Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atherosclerosis.

Y Sherer1, Y Shoenfeld

  • 1Department of Medicine B and Centre of Autoimmune Diseases, Sheba Medical Centre, Tel-Hashomer, 52621 Israel. shoenfel@post.tau.ac.il

Annals of the Rheumatic Diseases
|January 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thymoma, thymic hyperplasia, thymectomy and autoimmune diseases (Review).

International journal of oncology·2011
Same author

European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies.

Annals of the rheumatic diseases·2009
Same author

Infectious antibodies in systemic lupus erythematosus patients.

Lupus·2009
Same author

Common infectious agents prevalence in antiphospholipid syndrome.

Lupus·2009
Same author

Infections and autoimmune thyroid diseases: parallel detection of antibodies against pathogens with proteomic technology.

Autoimmunity reviews·2008
Same author

Bacterial triggers and autoimmune rheumatic diseases.

Clinical and experimental rheumatology·2008
Same journal

Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups.

Annals of the rheumatic diseases·2026
Same journal

A data-driven, weighted flare score that accurately predicts organ damage in systemic lupus erythematosus.

Annals of the rheumatic diseases·2026
Same journal

PD-1 signalling restrains pathogenic T peripheral helper and effector CD4⁺ T cell functions in rheumatoid arthritis.

Annals of the rheumatic diseases·2026
Same journal

Remission of refractory lupus nephritis is temporally associated with antitumour therapy, including durvalumab for endometrial carcinoma.

Annals of the rheumatic diseases·2026
Same journal

Mapping inequalities in rheumatology care in Europe: the first edition of the EULAR RheumaFacts project.

Annals of the rheumatic diseases·2026
Same journal

Commentary on 'Assessing the performance of AI chatbots in answering patients common questions about low back pain'.

Annals of the rheumatic diseases·2026
See all related articles

Atherosclerosis may be an autoimmune disease driven by cellular and humoral immune responses. Understanding this immune basis is key to developing new treatments for this cardiovascular condition.

Area of Science:

  • Immunology
  • Cardiovascular Science
  • Pathology

Background:

  • Atherosclerosis is a chronic inflammatory disease characterized by plaque buildup in arteries.
  • The precise immune mechanisms underlying atherosclerosis pathogenesis remain incompletely understood.
  • Investigating atherosclerosis as an autoimmune condition offers new therapeutic avenues.

Discussion:

  • This review explores the evidence for atherosclerosis as a cellular-mediated autoimmune disease.
  • It also examines the role of humoral immunity, including autoantibodies, in disease progression.
  • Distinguishing between cellular and humoral contributions is crucial for targeted interventions.

Key Insights:

  • Evidence suggests both T-cell mediated cellular immunity and autoantibody-driven humoral immunity contribute to atherosclerosis.

Related Experiment Videos

  • Specific immune cells and autoantigens are implicated in atherogenesis.
  • The interplay between innate and adaptive immunity is central to the disease process.

    • Outlook:

    • Further research is needed to fully elucidate the autoimmune basis of atherosclerosis.
    • Targeting specific immune pathways may lead to novel treatments for atherosclerosis.
    • Understanding the autoimmune component could redefine atherosclerosis management strategies.